Rheumatism

Research into possible treatments for individuals living with active rheumatic disease

Register
Illustratie ANIMA Research

Information

Open for enrollment
Condition
The medical condition or disease being investigated in the study.
Rheumatism
Reimbursement
Financial reimbursement provided to participants for their time and travel costs.
Yes
Age:
The minimum and maximum age required to be eligible for participation.
18-65y
Placebo
An inactive substance used as a comparator in the study. Some participants may receive a placebo instead of the investigational treatment.
No
Ethics Committee approval
Confirmation that the study has been reviewed and approved by an independent Ethics Committee, ensuring participant safety and scientific integrity.
Yes
Phase
The development stage of the investigational treatment, ranging from Phase I to Phase IV.
1
Biological sex
Indicates whether the study is open to all sexes or restricted to male or female participants.
All
Mensen
Safe and reliable participation

✓ Always under medical supervision
✓ Maximum focus on your data privacy (GDPR)
✓ Over +7,500 participants have gone before you

About this study project

Rheumatoid arthritis is a chronic autoimmune inflammatory condition primarily affecting the synovial joints, with significant implications for physical function and quality of life. This study investigates a potential pharmacological treatment for adults with confirmed active rheumatoid arthritis, conducted in collaboration with Reumacentrum Genk, under the clinical leadership of Dr. Philip Remans.

Rheumatoid arthritis is characterised by persistent synovial inflammation, resulting in progressive joint destruction and functional impairment. 

Clinical manifestations include:

  • Painful, swollen, and stiff synovial joints
  • Persistent fatigue and reduced physical endurance
  • Functional limitations in activities of daily living

The pathophysiology involves dysregulation of the immune system, including autoimmune responses and genetic predisposition, further modulated by environmental risk factors such as tobacco use and chronic psychosocial stress.

Study objective: 

This ANIMA Research clinical study evaluates potential therapeutic interventions for patients with rheumatoid arthritis presenting with inadequate response to prior treatment regimens. The study aims to:

  • Develop more efficacious pharmacological treatment options
  • Improve joint mobility and overall quality of life
  • Assess the safety and tolerability profile of investigational therapeutic agents
  • Men and women aged 18–75 years
  • Confirmed diagnosis of active rheumatoid arthritis
  • Inadequate response to prior therapeutic interventions
  1. Register via the online form; you will receive a confirmation e-mail
  2. Our team will contact you for further follow-up and to assess whether participation is clinically appropriate
  3. Begin participation under medical supervision, including a treatment period and follow-up visits

You will receive personalised guidance from our team of physicians and researchers throughout the study. You are encouraged to ask questions at any stage and will receive support at every step to ensure you feel informed and clinically well-supported.

By participating, you contribute to the clinical understanding of how adults diagnosed with rheumatoid arthritis respond to a potential therapeutic intervention. The data collected will support the further development of this treatment and may generate valuable evidence for future clinical care.

Approved by the Ethics Committee UZA/UAntwerpen (reference 2025-8206, project ID 8206)

Other ongoing study projects

Skin conditions

Illustratie ANIMA Research
18-70y

Depression

Illustratie ANIMA Research
18-99y

Sleep: Excessive

Slaap
18-65y

Cardiovascular

Illustratie ANIMA Research
18-95y

Rheumatism

Illustratie ANIMA Research
18-65y

Obesity

Obesitas
18-95y

Vaccine: Flu & COVID

Griep
18-95y

Alcohol use

Illustratie ANIMA Research
18-65y